Edgar Filing: TANDEM DIABETES CARE INC

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â TPG Group Holdings (SBS) Advisors, Inc.

2. Date of Event Requiring Statement (Month/Day/Year)
11/13/2013

3. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [TNDM]

(Last)

(First)

(Middle)

C/O TPG GLOBAL, LLC,Â 301 COMMERCE STREET, SUITE 3300

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

FORT WORTH,Â TXÂ 76102

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Preferred Stock	Â ⁽⁵⁾	Â ⁽⁵⁾	Common Stock	155,222	$ ⁽⁵⁾	I	See Explanation of Responses ⁽¹⁾ ⁽³⁾ ⁽⁴⁾
Series C Preferred Stock	Â ⁽⁵⁾	Â ⁽⁵⁾	Common Stock	559,211	$ ⁽⁵⁾	I	See Explanation of Responses ⁽¹⁾ ⁽³⁾ ⁽⁴⁾
Series D Preferred Stock	Â ⁽⁵⁾	Â ⁽⁵⁾	Common Stock	1,781,761	$ ⁽⁵⁾	I	See Explanation of Responses ⁽¹⁾ ⁽³⁾ ⁽⁴⁾
Warrant	Â ⁽²⁾	Â ⁽²⁾	Common Stock	169,157	$ ⁽²⁾	I	See Explanation of Responses (1) (2) (3), ⁽⁴⁾
Warrant	Â ⁽²⁾	Â ⁽²⁾	Common Stock	105,996	$ ⁽²⁾	I	See Explanation of Responses (1) (2) (3), ⁽⁴⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
TPG Group Holdings (SBS) Advisors, Inc. C/O TPG GLOBAL, LLC 301 COMMERCE STREET, SUITE 3300 FORT WORTH,Â TXÂ 76102	Â	Â X	Â	Â
BONDERMAN DAVID C/O TPG GLOBAL, LLC 301 COMMERCE STREET, SUITE 3300 FORT WORTH,Â TXÂ 76102	Â	Â X	Â	Â
COULTER JAMES G C/O TPG GLOBAL, LLC 301 COMMERCE STREET, SUITE 3300 FORT WORTH,Â TXÂ 76102	Â	Â X	Â	Â

Signatures

/s/ Ronald Cami, Vice President, TPG Group Holdings (SBS) Advisors, Inc. (6)		11/13/2013
^**Signature of Reporting Person		Date
/s/ Ronald Cami on behalf of David Bonderman (6)(7)		11/13/2013
^**Signature of Reporting Person		Date
/s/ Ronald Cami on behalf of James G. Coulter (6)(7)		11/13/2013
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	David Bonderman and James G. Coulter are officers and sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. ("Group Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnology GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 260,090 shares of Series B Preferred Stock (the "Series B") of Tandem Diabetes Care, Inc. (the "Issuer"), 937,014 shares of Series C Preferred Stock (the "Series C") of the Issuer and 2,985,519 shares of Series D Preferred Stock (the "Series D" and, together with the Series B and the Series C, the "Preferred Stock") of the Issuer.
(2)	TPG Biotech III also directly holds (i) a warrant issued on August 17, 2011 (the "2011 Warrant") now exercisable into shares of Common Stock, par value $0.001 per share, of the Issuer ("Common Stock") at any time until August 17, 2021 at an exercise price of $7.37 per share of Common Stock and (ii) a warrant issued on July 24, 2012 (the "2012 Warrant") now exercisable into shares of Common Stock at any time until July 24, 2022 at an exercise price of $7.37 per share of Common Stock. The exercise price of each of the 2011 Warrant and the 2012 Warrant is subject to certain adjustments.
(3)	Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any.
(4)	Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
(5)	Pursuant to the Fifth Amended and Restated Certificate of Incorporation of the Issuer, as amended, the shares of Series B, Series C and Series D are convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate in each case equal to one share of Common Stock per share of Preferred Stock. The initial conversion rates have been adjusted as a result of a 1-for-1.6756 reverse stock split of the Issuer's Common Stock.
Â Remarks: (6)Â TheÂ ReportingÂ PersonsÂ areÂ jointlyÂ filingÂ thisÂ FormÂ 3Â pursuantÂ toÂ RuleÂ 16a-3(j)Â underÂ theÂ ExchangeÂ Act. (7)Â RonaldÂ CamiÂ isÂ signingÂ onÂ behalfÂ ofÂ bothÂ Messrs.Â BondermanÂ andÂ CoulterÂ pursuantÂ toÂ theÂ authorizationÂ andÂ designationÂ lettersÂ datedÂ JulyÂ 1,Â 2013,Â whichÂ wereÂ previouslyÂ filedÂ withÂ theÂ SecuritiesÂ andÂ ExchangeÂ Commission.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.